The global biomarkers market is estimated to reach USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Growth in the market is mainly driven by factors such as increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for biomarker research. On the other hand, high capital investments and low cost-benefit ratio, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection and storage are the major factors restraining the growth of this market.
McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects. The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016. It is the largest and fastest growing fine industry in the modern biopharmaceutical industry. According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015. McAbs occupy six seats of the world’s top ten best-selling drugs.